Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study

Larimar Therapeutics, Inc.

2025-Q3 EPS reported -$1.50 vs consensus -$0.41 ▼ miss (-264.0%)

Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.
100% of participants (n=10) achieved skin FXN levels similar to asymptomatic carriers after 6 months of daily nomlabofusp in open-label study.
Anaphylaxis occurred in 7 of 65 total participants; new modified starting dose regimen implemented to mitigate risk, agreed with FDA.
BLA submission seeking accelerated approval targeted for Q2 2026, with $175.4M cash runway into Q4 2026.
Consistent directional improvement across mFARS, FARS-ADL, 9-HPT, and MFIS after 1 year versus worsening in FACOMS reference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.